A proteomic analysis of p53-independent induction of apoptosis by bortezomib in 4T1 breast cancer cell line

Journal of Proteomics

Volumn 113, Issue , 2015, Pages 315-325

  Yerlikaya, Azmi ^a   Okur, Emrah ^a   Baykal, Ahmet Tarik ^b   Acilan, Ceyda ^c   Boyaci, Ihsan ^b   Ulukaya, Engin ^d  

^a DUMLUPINAR UNIVERSITY   (Turkey)

^b ISTANBUL MEDIPOL UNIVERSITY   (Turkey)

^c SCIENTIFIC AND TECHNOLOGICAL RESEARCH COUNCIL OF TURKEY   (Turkey)

^d ULUDAG UNIVERSITY   (Turkey)

Author keywords

Apoptosis; Bortezomib; Cancer; Proteasome; Proteomics; Ubiquitin

Indexed keywords

BORTEZOMIB; CARD10 PROTEIN; CASPASE ACTIVATED DEOXYRIBONUCLEASE; CELL PROTEIN; GLUCOSE REGULATED PROTEIN 78; NON ATPASE ASE REGULATORY SUBUNIT 14; PROTEASOME; PROTEIN P53; SEQUESTOSOME 1; TCEB2 PROTEIN; TRP53BP2 PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; UBIQUITIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ATP DEPENDENT 26S PROTEASE; BORONIC ACID DERIVATIVE; DNA; PROTEOME; PYRAZINE DERIVATIVE; TP53 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CONTROLLED STUDY; DNA REPLICATION; ENERGY YIELD; LIQUID CHROMATOGRAPHY; NUCLEIC ACID METABOLISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN PROCESSING; PROTEOMICS; TANDEM MASS SPECTROMETRY; BIOSYNTHESIS; BREAST NEOPLASMS; DRUG EFFECTS; ENERGY METABOLISM; FEMALE; HUMAN; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA REPLICATION; DNA, NEOPLASM; ENERGY METABOLISM; FEMALE; HUMANS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN FOLDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEOME; PROTEOMICS; PYRAZINES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84938493066     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2014.09.010     Document Type: Article

References (47)

1. Wojcik C, DeMartino GN. Intracellular localization of proteasomes. Int J Biochem Cell Biol 2003;35(5):579-89.
2. Hough R, Pratt G, Rechsteiner M. Purification of two high molecular weight proteases from rabbit reticulocyte lysate. J Biol Chem 1987;262(17):8303-13.
3. Lecker SH, Goldberg AL, Mitch WE. Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. J Am Soc Nephrol 2006;17(7):1807-19.
4. Yerlikaya A, Stanley BA. S-adenosylmethionine decarboxylase degradation by the 26 S proteasome is accelerated by substrate-mediated transamination. J Biol Chem 2004;279(13):12469-78.
5. Yerlikaya A, Yontem M. The significance of ubiquitin proteasome pathway in cancer development. Recent Pat Anticancer Drug Discov 2013;8(3):298-309.
6. Finley D. Recognition and processing of ubiquitin-protein conjugates by the proteasome. Annu Rev Biochem 2009;78: 477-513.
7. Murakami Y, Matsufuji S, Kameji T, Hayashi S, Igarashi K, Tamura T, et al. Ornithine decarboxylase is degraded by the 26S proteasome without ubiquitination. Nature 1992; 360(6404):597-9.
8. Burger AM, Seth AK. The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications. Eur J Cancer 2004;40(15):2217-29.
9. Frankland-Searby S, Bhaumik SR. The 26S proteasome complex: an attractive target for cancer therapy. Biochim Biophys Acta 2012;1825(1):64-76.
10. Hoffmann O, Heubner M, Anlasik T, Winterhalter M, Dahlmann B, Kasimir-Bauer S, et al. Circulating 20S proteasome in patients with non-metastasized breast cancer. Anticancer Res 2011;31(6):2197-201.
11. Chen L, Madura K. Increased proteasome activity, ubiquitin-conjugating enzymes, and eEF1A translation factor detected in breast cancer tissue. Cancer Res 2005;65(13): 5599-606.
12. Pan J, Zhang Q, Wang Y, You M. 26S proteasome activity is down-regulated in lung cancer stem-like cells propagated in vitro. PLoS One 2010;5(10):e13298.
13. Crawford LJ, Walker B, Irvine AE. Proteasome inhibitors in cancer therapy. J Cell Commun Signal 2011;5(2):101-10.
14. Kuhn DJ, Orlowski RZ, Bjorklund CC. Second generation proteasome inhibitors: carfilzomib and immunoproteasome-specific inhibitors (IPSIs). Curr Cancer Drug Targets 2011;11(3):285-95.
15. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004;4(5):349-60.
16. Field-Smith A, Morgan GJ, Davies FE. Bortezomib (Velcade®) in the treatment of multiple myeloma. Ther Clin Risk Manag 2006;2(3):271-9.
17. Buac D, Shen M, Schmitt S, Kona FR, Deshmukh R, Zhang Z, et al. From Bortezomib to other Inhibitors of the proteasome and beyond. Curr Pharm Des 2013;19(22):4025-38.
18. Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 2008; 14(6):1649-57.
19. Lopes UG, Erhardt P, Yao R, Cooper GM. p53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem 1997;272(20):12893-6.
20. Yerlikaya A, Okur E, Ulukaya E. The p53-independent induction of apoptosis in breast cancer cells in response to proteasome inhibitor bortezomib. Tumour Biol 2012;33(5): 1385-92.
21. Boccadoro M, Morgan G, Cavenagh J. Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int 2005;5(1):18.
22. Yerlikaya A, Kimball SR, Stanley BA. Phosphorylation of eIF2alpha in response to 26S proteasome inhibition is mediated by the haem-regulated inhibitor (HRI) kinase. Biochem J 2008;412(3):579-88.
23. Valentiner U, Haane C, Nehmann N, Schumacher U. Effects of bortezomib on human neuroblastoma cells in vitro and in a metastatic xenograft model. Anticancer Res 2009;29(4): 1219-25.
24. Wisniewski JR, Zougman A, Nagaraj N, Mann M. Universal sample preparation method for proteome analysis. Nat Methods 2009;6(5):359-62.
25. Rosenegger D, Wright C, Lukowiak K. A quantitative proteomic analysis of long-term memory. Mol Brain 2010;3:9.
26. Wright C, Edelmann M, diGleria K, Kollnberger S, Kramer H, McGowan S, et al. Ankylosing spondylitis monocytes show upregulation of proteins involved in inflammation and the ubiquitin proteasome pathway. Ann Rheum Dis 2009;68(10): 1626-32.
27. Cockman ME, Webb JD, Kramer HB, Kessler BM, Ratcliffe PJ. Proteomics-based identification of novel factor inhibiting hypoxia-inducible factor (FIH) substrates indicates widespread asparaginyl hydroxylation of ankyrin repeat domain-containing proteins. Mol Cell Proteomics 2009;8(3): 535-46.
28. D'Aguanno S, D'Alessandro A, Pieroni L, Roveri A, Zaccarin M, Marzano V, et al. New insights into neuroblastoma cisplatin resistance: a comparative proteomic and meta-mining investigation. J Proteome Res 2011;10(2):416-28.
29. Vissers JP, Langridge JI, Aerts JM. Analysis and quantification of diagnostic serum markers and protein signatures for Gaucher disease. Mol Cell Proteomics 2007; 6(5):755-66.
30. Hacariz O, Sayers G, Baykal AT. A proteomic approach to investigate the distribution and abundance of surface and internal Fasciola hepatica proteins during the chronic stage of natural liver fluke infection in cattle. J Proteome Res 2012; 11(7):3592-604.
31. Yerlikaya A, Erin N. Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade. Int J Mol Med 2008;22(6):817-23.
32. Wang H, Mohammad RM, Werdell J, Shekhar PV. p53 and protein kinase C independent induction of growth arrest and apoptosis by bryostatin 1 in a highly metastatic mammary epithelial cell line: In vitro versus in vivo activity. Int J Mol Med 1998;1(6):915-23.
33. Delie F, Petignat P, Cohen M. GRP78 protein expression in ovarian cancer patients and perspectives for a drug-targeting approach. J Oncol 2012;2012:468615.
34. Hsu YL, Wu CY, Hung JY, Lin YS, Huang MS, Kuo PL. Galectin-1 promotes lung cancer tumor metastasis by potentiating integrin alpha6beta4 and Notch1/Jagged2 signaling pathway. Carcinogenesis 2013;34(6):1370-81.
35. Strauss SJ, Higginbottom K, Juliger S, Maharaj L, Allen P, Schenkein D, et al. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines. Cancer Res 2007;67(6):2783-90.
36. Oerlemans R, Franke NE, Assaraf YG, Cloos J, van Zantwijk I, Berkers CR, et al. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 2008;112(6):2489-99.
37. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348(26):2609-17.
38. Chen Z, Ricker JL, Malhotra PS, Nottingham L, Bagain L, Lee TL, et al. Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms. Mol Cancer Ther 2008;7(7):1949-60.
39. Doll D, Sarikas A, Krajcik R, Zolk O. Proteomic expression analysis of cardiomyocytes subjected to proteasome inhibition. Biochem Biophys Res Commun 2007;353(2):436-42.
40. Wang HQ, Du ZX, Zhang HY, Gao DX. Different induction of GRP78 and CHOP as a predictor of sensitivity to proteasome inhibitors in thyroid cancer cells. Endocrinology 2007;148(7): 3258-70.
41. Grossin L, Etienne S, Gaborit N, Pinzano A, Cournil-Henrionnet C, Gerard C, et al. Induction of heat shock protein 70 (Hsp70) by proteasome inhibitor MG 132 protects articular chondrocytes from cellular death in vitro and in vivo. Biorheology 2004;41(3-4):521-34.
42. Myeku N, Figueiredo-Pereira ME. Dynamics of the degradation of ubiquitinated proteins by proteasomes and autophagy: association with sequestosome 1/p62. J Biol Chem 2011;286(25):22426-40.
43. Berke SJ, Paulson HL. Protein aggregation and the ubiquitin proteasome pathway: gaining the UPPer hand on neurodegeneration. Curr Opin Genet Dev 2003;13(3):253-61.
44. Dolcet X, Llobet D, Encinas M, Pallares J, Cabero A, Schoenenberger JA, et al. Proteasome inhibitors induce death but activate NF-kappaB on endometrial carcinoma cell lines and primary culture explants. J Biol Chem 2006;281(31): 22118-30.
45. Lin CP, Ban Y, Lyu YL, Liu LF. Proteasome-dependent processing of topoisomerase I-DNA adducts into DNA double strand breaks at arrested replication forks. J Biol Chem 2009; 284(41):28084-92.
46. Cruceanu C, Alda M, Nagy C, Freemantle E, Rouleau GA, Turecki G. H3K4 tri-methylation in synapsin genes leads to different expression patterns in bipolar disorder and major depression. Int J Neuropsychopharmacol 2013;16(2):289-99.
47. Yerlikaya A, Okur E, Baykal AT, Acilan C, Boyaci I, Ulukaya E. Data for a proteomic analysis of p53-independent induction of apoptosis by bortezomib. Data in Brief 2014. http://dx.doi.org/10.1016/j.dib.2014.09.003 (in press).